The Hon. Bill Baer

Bill Baer is a visiting fellow in Governance Studies at the Brookings Institute. He is one of the world’s best known and respected antitrust/competition enforcers. Bill is the only person to have led antitrust enforcement at both U.S. antitrust agencies, serving as Assistant Attorney General in charge of the Antitrust Division of the US Department of Justice from 2013 to 2016, and as Director of the Bureau of Competition at the Federal Trade Commission from 1995 to 1999.

Bill worked at the Federal Trade Commission on two different occasions: from 1995-99, as Director of the Bureau of Competition; and from 1975-1980 as Attorney Advisor to the Chairman and Assistant General Counsel for Legislation and Congressional Relations. While not in public service Bill headed the highly regarded antitrust practice at Arnold & Porter, representing a broad range of companies in US and international cartel investigations, antitrust litigation, and mergers and acquisition reviews by antitrust enforcers, including the DOJ, FTC, state attorneys general, and the European Commission.

Bill received his JD in 1975 from Stanford Law School, where he served as Senior Article Editor of The Stanford Law Review, and his BA in 1972 from Lawrence University, which recently awarded him its Distinguished Alumni Achievement Award.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More